Hypocrellin A
Based on 2 publication(s) in Google Scholar
Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.73%
- No. CAS: 77029-83-5
- Fòrmula: C30H26O10
- Peso molecular:546.52
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0453
HypericinPKC Inhibitor -
HY-N0063
Punicalagin3CLpro Inhibitor -
HY-N0498
Nitidine chlorideAnti-malarial Agent -
HY-K0301
Cell Counting Kit-8 -
HY-B0923
DanthronAMPK Activator -
HY-N2575R
Hypocrellin A (Standard)Photosensitizer -
HY-13689
Go 6983PKC Inhibitor -
HY-10230
MidostaurinMulti-targeted Protein Kinase Inhibitor -
HY-10343
SotrastaurinPan-PKC Inhibitor -
HY-10183
Go6976PKC Inhibitor -
HY-15141
StaurosporinePKC/PKA Inhibitor -
HY-B1743A
Puromycin dihydrochlorideProtein Synthesis Inhibitor
Publications Citing Use of MedChemExpress (MCE) Hypocrellin A
MoreVer todos los productos específicos de isoformas Parasite
MoreVer todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
IC50 & Target
|
Leishmania |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
0.55 μM
Compound: 7
|
Cytotoxicity against human K562 cells treated for 4 hrs followed irradiated with invisible light for 1000 seconds by by MTT assay
Cytotoxicity against human K562 cells treated for 4 hrs followed irradiated with invisible light for 1000 seconds by by MTT assay
|
[PMID: 22276650] |
| K562 | IC50 |
7.47 μM
Compound: 7
|
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 22276650] |
In Vitro
Hypocrellin A (150 nM; 24 h) significantly reduces the release of VEGF and ET-1 from human umbilical vein endothelial cells (HUVECs) incubated in glucose (20 mM)[1].
Hypocrellin A shows good activity against Candida albicans (IC50=0.65 μg/ml) and moderates activity against Staphylococcus aureus, MRSA, Pseudomonas aeruginosa, and Mycobacterium intracellularis[4].
Hypocrellin A (0.055-5.5 µM) loses the infectivity of both HIV-1 and VSV in a concentration-dependent manner when treats with 1 J/cm2 white light[5].
Hypocrellin A (5 µM; 6 h) increases the secretion of multiple anti-angiogenic factors in LN229 glioma, U937 macrophages and SVHCEC endothelial cells after photochemotherapy[6].
Hypocrellin A (0.25-1 µM; 48 h) has a negative impact on cell viability, migration, invasion and apoptosis of three non-small cell lung cancer cells, H460, PC-9 and H1975[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cells (HUVECs) incubated in glucose (20 mM)
-
Concentration:150 nM
-
Incubation Time:24 h
-
Result:Reduced VEGF protein expression.
-
Cell Line:LN229 glioma, U937 macrophages, and SVHCEC endothelial cells
-
Concentration:5 µM
-
Incubation Time:6 h
-
Result:Induced production of roangiogenic VEGF (vascular endothelial growth factor) and of antiangiogenic sFlt-1, angiostatin, p43, allograft inflammatory factor-1, and connective tissue growth factor.
-
Cell Line:H460, PC-9 and H1975 cell lines
-
Concentration:0.25, 0.5 and 1 µM
-
Incubation Time:48 h
-
Result:The IC50 values for H460, PC-9 and H1975 cell lines were 0.2706, 0.6223 and 0.2223 µM, respectively.
-
Cell Line:H460, PC-9 and H1975 cell lines
-
Concentration:0.25, 0.5 and 1 µM
-
Incubation Time:48 h
-
Result:Increased the expression levels of pro-apoptotic proteins BAX and Cl-PARP, and decreased the expression level of anti-apoptotic protein BCL-2.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H460 cells were inoculated subcutaneously on the backs of BALB/c nude mice[8]
-
Dosage:2.5 and 5 mg/kg
-
Administration:i.p.; Inject once every two days for fourteen days
-
Result:Induced the expression of the pro-apoptotic protein BAX and inhibited the expression of the anti-apoptotic protein BCL-2 in NSCLC tumors.
Chemical Information
-
No. CAS 77029-83-5
-
Appearance Solid
-
Peso molecular 546.52
-
Fòrmula C30H26O10
-
Color Brown to red
-
SMILES
COC(C1=O)=C2C3=C(C1=C(C=C4OC)O)C4=C(C(OC)=CC(O)=C56)C5=C3C(CC(C)(O)C2C(C)=O)=C(OC)C6=O
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvente y solubilidad
In Vitro:
DMSO : 16.67 mg/mL (30.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.57 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (291 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Dang L, et al. Effects of hypocrellin A on expression of vascular endothelial growth factor and endothelin-1 in human umbilical endothelial cells. Am J Chin Med. 2007;35(4):713-23. [Content Brief]
[2]. Ma YJ, et al. Enhanced Production of Hypocrellin A in Submerged Cultures of Shiraia bambusicola by Red Light. Photochem Photobiol. 2019 May;95(3):812-822. [Content Brief]
[3]. Fehr MJ, et al. Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Biochemistry. 1995 Dec 5;34(48):15845-8. [Content Brief]
[4]. Ma G, et al. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob Agents Chemother. 2004 Nov;48(11):4450-2. [Content Brief]
[5]. Hirayama, et al. "Photoinactivation of virus infectivity by hypocrellin A." Photochemistry and photobiology 66.5 (1997): 697-700. [Content Brief]
[6]. Deininger, et al. "Release of regulators of angiogenesis following Hypocrellin-A and-B photodynamic therapy of human brain tumor cells." Biochemical and Biophysical Research Communications 298.4 (2002): 520-530. [Content Brief]
[7]. Yujie, et al. "Photodynamic antimicrobial activity of hypocrellin A." Journal of Photochemistry and Photobiology B: Biology 103.1 (2011): 29-34. [Content Brief]
[8]. Yang, et al. "Hypocrellin A exerts antitumor effects by inhibiting the FGFR1 signaling pathway in non-small cell lung cancer." Phytomedicine 97 (2022): 153924. [Content Brief]
[9]. Guo, et al. "Evaluation of hypocrellin A-loaded lipase sensitive polymer micelles for intervening methicillin-resistant Staphylococcus Aureus antibiotic-resistant bacterial infection." Materials Science and Engineering: C 106 (2020): 110230. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8298 mL | 9.1488 mL | 18.2976 mL | 45.7440 mL |
| 5 mM | 0.3660 mL | 1.8298 mL | 3.6595 mL | 9.1488 mL | |
| 10 mM | 0.1830 mL | 0.9149 mL | 1.8298 mL | 4.5744 mL | |
| 15 mM | 0.1220 mL | 0.6099 mL | 1.2198 mL | 3.0496 mL | |
| 20 mM | 0.0915 mL | 0.4574 mL | 0.9149 mL | 2.2872 mL | |
| 25 mM | 0.0732 mL | 0.3660 mL | 0.7319 mL | 1.8298 mL | |
| 30 mM | 0.0610 mL | 0.3050 mL | 0.6099 mL | 1.5248 mL |
Hypocrellin A Related Classifications
HY-N2575 Related Classifications
Powered by Bioz